Long-acting injectables have emerged as a game-changing solution in the rapidly evolving world of healthcare. While patients around the globe are increasingly benefitting from the durable efficacy provided by these treatments, the development and in some cases adoption of these innovative treatments has been slow. Key challenges related to in some cases complex manufacturing, limited in vivo – in vitro correlation, and demanding regulatory and clinical framework have contributed to the relative rarity of long-acting products. Long-acting injectables have improved the quality of life for patients. These innovative treatments have been proven to enhance effectiveness and improve patient compliance with dosing. As the demand for these advancements continues to grow, there has been a wide range of delivery technologies developed for various pharmaceutical products.
The webinar will focus on the landscape of long-acting injectables. We welcome three global experts in the field, Prof. René Holm of the University of Southern Denmark, Dr. Peter Markland of Tolmar Pharmaceuticals, and Dr. Mika Jokinen of DelSiTech to provide their unique perspectives on the long-acting injectable technology space as it stands today. Dr. René Holm will lead us through the long-acting injectables landscape enabling more effective treatment. Dr. Peter Markland from Tolmar will express the benefits of long-acting injectables in treating various diseases. Dr. Mika Jokinen from DelSiTech will present Silica Matrix technology as a sustained delivery from subcutaneous to intravitreal administration routes.
Learning objective:
- Long acting injectables
- Parenteral drug delivery
- Silica Matrix technology
- Ophthalmology